Table 138A.5Survival after Relapse on the CCG-100 Series182

Time of RelapseNN(%)6-year Freedom from 2nd Adverse Event (SD)
Isolated marrow64216% ± 2%
Early233 (36)5% ± 2%
Intermediate194 (30)10% ± 4%
Late215 (33)33% ± 4%
Combined marrow12029% ± 4%
Early34 (28)9% ± 5%
Intermediate26 (22)11% ± 6%
Late60 (50)48% ± 7%
Isolated CNS22037% ± 3%
Early102 (46)24% ± 5%
Intermediate84 (38)44% ± 5%
Late34 (17)59% ± 9%
Isolated testes11264% ± 5%
Early22 (20)48% ± 11%
Intermediate24 (21)44% ± 11%
Late66 (59)76% ± 6%

Early = <18 months; Intermediate = 19–36 months; Late = > 36 months.

From: Chapter 138A, Childhood Acute Lymphoblastic Leukemia

Cover of Holland-Frei Cancer Medicine
Holland-Frei Cancer Medicine. 5th edition.
Bast RC Jr, Kufe DW, Pollock RE, et al., editors.
Hamilton (ON): BC Decker; 2000.
© 2000, BC Decker Inc.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.